MAPT and Alzheimer disease: Trials of intranasal (IN) delivery of insulin for AD has inspired a study on IN rapamycin in a mouse model of Down syndrome, finding that radial arm maze and object recognition cognitive dysfunctions are rescued along with positive effects on measures of autophagy and tau phosphorylation [345].